Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 268

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 268
---
,000 |   |
| Stock Issued for Payment of Deferred Compensation                                                                 |     | $    |    520,000 |   |     | $    |          - |   |
| Stock Issued for Acquisition of Intangibles                                                                       |     | $    |     33,895 |   |     | $    |          - |   |
| Fair Value of Warrants Issued to Underwriters                                                                     |     | $    |    301,416 |   |     | $    |          - |   |
| Reclassification of Liability-classified Warrants to Equity-classified                                            |     | $    |    838,748 |   |     | $    |          - |   |

See accompanying notes to these consolidated financial statements which are an integral part of these consolidated financial statements. F-39 60 DEGREES PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. NATURE OF OPERATIONS 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia. Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095units at a price of $ 5.30per unit for $ 6,454,325in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted